Cargando…

Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer

Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains a serious concern due to the limitations associated with currently available cancer management strate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Girisa, Sosmitha, Parama, Dey, Harsha, Choudhary, Banik, Kishore, Kunnumakkara, Ajaikumar B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400725/ https://www.ncbi.nlm.nih.gov/pubmed/36046484 http://dx.doi.org/10.37349/etat.2020.00019

Ejemplares similares

Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer
por: Girisa, Sosmitha, et al.
Publicado: (2021)

Targeting AKT/mTOR in Oral Cancer: Mechanisms and Advances in Clinical Trials
por: Harsha, Choudhary, et al.
Publicado: (2020)

Reiterating the Emergence of Noncoding RNAs as Regulators of the Critical Hallmarks of Gall Bladder Cancer
por: Rana, Varsha, et al.
Publicado: (2021)

Emerging roles of cardamonin, a multitargeted nutraceutical in the prevention and treatment of chronic diseases
por: Daimary, Uzini Devi, et al.
Publicado: (2020)

The promising potential of piperlongumine as an emerging therapeutics for cancer
por: Parama, Dey, et al.
Publicado: (2021)

COVID-19, cytokines, inflammation, and spices: How are they related?
por: Kunnumakkara, Ajaikumar B., et al.
Publicado: (2021)

Sorcin a Potential Molecular Target for Cancer Therapy
por: Shabnam, Bano, et al.
Publicado: (2018)

Resveratrol Modulates Chemosensitisation to 5-FU via β1-Integrin/HIF-1α Axis in CRC Tumor Microenvironment
por: Brockmueller, Aranka, et al.
Publicado: (2023)

Calebin A targets the HIF-1α/NF-κB pathway to suppress colorectal cancer cell migration
por: Brockmueller, Aranka, et al.
Publicado: (2023)

Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
por: Hegde, Mangala, et al.
Publicado: (2023)

Unraveling the Potential Role of NEDD4-like E3 Ligases in Cancer
por: Jayaprakash, Sujitha, et al.
Publicado: (2022)

Targeting Autophagy Using Long Non-Coding RNAs (LncRNAs): New Landscapes in the Arena of Cancer Therapeutics
por: Kumar, Aviral, et al.
Publicado: (2023)

Potential of Zerumbone as an Anti-Cancer Agent
por: Girisa, Sosmitha, et al.
Publicado: (2019)

FBXW7 in Cancer: What Has Been Unraveled Thus Far?
por: Sailo, Bethsebie Lalduhsaki, et al.
Publicado: (2019)

Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases
por: Sajeev, Anjana, et al.
Publicado: (2022)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

An Update on Pharmacological Potential of Boswellic Acids against Chronic Diseases
por: Roy, Nand Kishor, et al.
Publicado: (2019)

Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases
por: Kunnumakkara, Ajaikumar B., et al.
Publicado: (2018)

Demystifying the Functional Role of Nuclear Receptors in Esophageal Cancer
por: Jayaprakash, Sujitha, et al.
Publicado: (2022)

Morphologic Damage of Rat Alveolar Epithelial Type II Cells Induced by Bile Acids Could Be Ameliorated by Farnesoid X Receptor Inhibitor Z-Guggulsterone In Vitro
por: Wang, Jieqin, et al.
Publicado: (2016)

An Investigation on the Therapeutic Potential of Butein, A Tretrahydroxychalcone Against Human Oral Squamous Cell Carcinoma
por: Bordoloi, Devivasha, et al.
Publicado: (2019)

Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties
por: Henamayee, Sahu, et al.
Publicado: (2020)

Potential therapeutic targets of Guggulsterone in cancer
por: Bhat, Ajaz A., et al.
Publicado: (2017)

Chronic diseases, inflammation, and spices: how are they linked?
por: Kunnumakkara, Ajaikumar B., et al.
Publicado: (2018)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Targeting NF-κB Signaling by Calebin A, a Compound of Turmeric, in Multicellular Tumor Microenvironment: Potential Role of Apoptosis Induction in CRC Cells
por: Buhrmann, Constanze, et al.
Publicado: (2020)

Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects
por: Gangwar, Shailendra Kumar, et al.
Publicado: (2022)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer
por: Ranaware, Abhishek Manoj, et al.
Publicado: (2018)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

TIPE2 Induced the Proliferation, Survival, and Migration of Lung Cancer Cells Through Modulation of Akt/mTOR/NF-κB Signaling Cascade
por: Bordoloi, Devivasha, et al.
Publicado: (2019)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
por: Mueller, Michaela, et al.
Publicado: (2015)

Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents
por: Shinozawa, Emiko, et al.
Publicado: (2018)

A Regioselective Synthesis of E-Guggulsterone
por: Ham, Jungyeob, et al.
Publicado: (2011)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
por: Finamore, Claudia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_488aarlt4nhu6l64gt7pe1ii4t